Skip to main content
. Author manuscript; available in PMC: 2021 Aug 12.
Published in final edited form as: J Med Chem. 2020 Oct 23;63(21):12642–12665. doi: 10.1021/acs.jmedchem.0c00943

Figure 6.

Figure 6.

SARDs degrade enzalutamide resistance conferring escape mutant AR. Enzalutamide (4)-resistant (Enz-R) LNCaP cells (MR49F) (top panel) or 22RV1 cells (bottom panel) were maintained in charcoal-stripped, serum containing medium for 2 d and treated with 0.1 nM R1881 (agonist) and a titration of the SARD or 4 as indicated in the figure. Twenty-four hours after treatment, the cells were harvested and protein-extracted, and the proteins were blotted with AR-N20 antibody. Blots were stripped and reprobed with a GAPDH antibody. The ratio of AR to GAPDH or each lane is given under each blot.